Herter & Co. – a Teneo company has advised KD Pharma Group (“KD Pharma”) on its first capital markets issue, refinancing its existing debt facilities.
KD Pharma is one of the leading manufacturers of highly purified Omega-3 fatty acids for pharmaceutical as well as nutraceutical products. In 2013, capiton acquired a majority stake in the group. Since then, KD Pharma has achieved significant growth of turnover and profit and in October 2024 successfully completed the acquisition of dsm-firmenich’s Marine Lipids business.
The acquisition included dsm-firmenich’s Marine Lipids omega-3 fish oil business for the food and beverage, dietary supplement and pharmaceutical markets, as well as the MEG-3® brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in the enlarged group.
Herter & Co. – a Teneo company worked closely with the company and the sponsor throughout the whole process. The result is an overall financing package of a five-year €180m senior-secured bond which will be complemented by a €25m super senior RCF.
DNB Markets, a part of DNB Bank ASA, acted as Sole Manager in the bond issue. The bond will be listed on the Oslo Stock Exchange and the Frankfurt Open Market. Net proceeds from the bond issue will be used to refinance existing debt and for general corporate purposes of the group.
Herter & Co. – a Teneo company acted as sole debt advisor to the company in this transaction.
The KD Pharma Group is a CDMO that creates health solutions in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of Omega-3 fatty acids for the pharmaceutical and nutraceutical markets, formulation and encapsulation services, with over 710 employees and a presence in the UK, Norway, Germany, Switzerland, Canada, Peru and the U.S. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents.
